Hillenbrand (HI) investors back merger and advisory pay proposals at special meeting
Rhea-AI Filing Summary
Hillenbrand, Inc. reported the results of a special shareholder meeting held on January 8, 2026 to vote on its previously announced merger with affiliates of Lone Star Fund XII. Shareholders approved the Agreement and Plan of Merger among Hillenbrand, LSF12 Helix Parent, LLC, and LSF12 Helix Merger Sub, Inc., with 58,533,478 votes for, 353,769 against, and 47,809 abstentions.
Shareholders also approved, on an advisory basis, the merger-related compensation for Hillenbrand’s named executive officers, with 52,525,941 votes for, 6,165,726 against, and 243,389 abstentions. A proposal to permit adjournment of the meeting, if needed to solicit additional proxies, received 54,819,736 votes for, 3,051,176 against, and 1,064,144 abstentions. The company noted that completing the merger still depends on satisfying or waiving customary closing conditions, including required regulatory approvals.
Positive
- None.
Negative
- None.
Insights
Shareholders strongly approved Hillenbrand’s merger agreement and related pay, but closing still awaits regulatory and other customary conditions.
Hillenbrand disclosed that shareholders approved the merger agreement with affiliates of Lone Star Fund XII by a wide margin, with 58,533,478 votes in favor versus 353,769 against. This indicates broad support among voting shareholders for the plan to merge Hillenbrand with LSF12 Helix Merger Sub, Inc., leaving Hillenbrand as a wholly owned subsidiary of LSF12 Helix Parent, LLC.
The advisory vote on merger-related executive compensation also passed, with 52,525,941 votes for and 6,165,726 against, signaling acceptance of the disclosed pay arrangements tied to the transaction. Shareholders further backed the adjournment authority proposal, though the company did not indicate that an adjournment was required. The company emphasized that completion of the merger remains contingent on customary closing conditions, including obtaining required regulatory approvals, so the actual closing timing and outcome depend on those external processes.